Hospices Civils de Lyon (HCL), Hôpital Universitaire Femme-Mère-Enfant, service de pneumologie pédiatrique, Lyon, France.
Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Immuno-Hématologie pédiatrique, Paris, France.
Eur J Pediatr. 2019 Dec;178(12):1833-1839. doi: 10.1007/s00431-019-03447-z. Epub 2019 Sep 4.
There is little data on the long-term respiratory development of children after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We describe the respiratory assessment 10 years after allo-HSCT of 35 children transplanted between 2000 and 2004. During this period, 90 children were transplanted at our center. Twenty-five children died, thirty were lost to follow-up, and thirty-five came to have a pulmonary investigation. The thirty-five participants answered a questionnaire asking if they had pulmonary symptoms, and pulmonary function tests (PFTs) were performed. The median age of these children 10 years after the transplant was 16 years old. Just over a third of them had pulmonary symptoms. Among them, 5/13 (38%) had bronchiolitis obliterans syndrome (BOS). The majority of children (62.8%) did not have respiratory symptoms. PFTs were abnormal in one-third of asymptomatic children, revealing restrictive lung disease that was always mild to moderate (p = 0.02).Conclusion: In the long term, research at the time of the medical examination for the presence of chronic cough, shortness of breath on exertion, or wheezing helps to guide the clinician as to the need for further lung exploration. Similarly, informing patients and their families about these symptoms, which can be underestimated, should allow for more specific management.What is Known:• Pulmonary complications are a major cause of hematopoietic stem cell transplantation (HSCT) morbidity and mortality.• A long time after allogeneic HSCT, pulmonary function tests abnormalities may occur in children, but it is not always related to symptoms.What is New:• The occurrence of respiratory symptoms: cough, dyspnea on exertion, chronic bronchitis, and wheezing should be systematically investigated in the follow-up of allografted patients, even at a distance.• The presence of respiratory symptoms should lead to a respiratory functional investigation to detect the presence of an obstructive syndrome.
关于异基因造血干细胞移植 (allo-HSCT) 后儿童长期呼吸系统发育的数据很少。我们描述了 2000 年至 2004 年间移植的 35 名儿童在 allo-HSCT 后 10 年的呼吸系统评估。在此期间,我们中心移植了 90 名儿童。25 名儿童死亡,30 名儿童失访,35 名儿童接受了肺部调查。这 35 名参与者回答了一份问卷,询问他们是否有肺部症状,并进行了肺功能测试 (PFT)。这些儿童在移植后 10 年的中位年龄为 16 岁。超过三分之一的儿童有肺部症状。其中,13 人中有 5 人(38%)患有闭塞性细支气管炎综合征 (BOS)。大多数儿童(62.8%)没有呼吸道症状。三分之一无症状儿童的 PFT 异常,显示出总是轻度至中度的限制性肺疾病(p=0.02)。结论:长期以来,在医疗检查时研究是否存在慢性咳嗽、运动时呼吸困难或喘息有助于指导临床医生是否需要进一步进行肺部探索。同样,告知患者及其家属这些症状(可能被低估),应允许进行更具体的管理。已知内容:• 肺部并发症是造血干细胞移植 (HSCT) 发病率和死亡率的主要原因。• 在异基因 HSCT 后很长一段时间,儿童可能会出现肺功能测试异常,但并不总是与症状有关。新内容:• 出现呼吸道症状:咳嗽、运动时呼吸困难、慢性支气管炎和喘息,即使在远处,也应在异基因移植患者的随访中系统地进行调查。• 存在呼吸道症状应导致进行呼吸功能检查以检测阻塞性综合征的存在。